Skip to main content

Table 3 Results of univariate and multivariate analyses of risk factors of acute nausea among 312 cases with palonosetron receiving MEC

From: Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens

 

Univariate

Multivariate

n

OR

95% CI

P-value

OR

95% CI

P-value

Age < 75 vs. ≥75 years

312

n.c.

    

–

    

Sex Female (vs. Male)

312

1.162

0.510

,

2.647

0.720

–

    

Anti-cancer drug

312

     

–

    

 L-OHP

178

1.000

 

ref

       

 CPT11

60

1.676

0.636

,

4.420

0.296

     

 CBDCA

74

0.920

0.316

,

2.679

0.878

     

Oral 5-FU

312

     

–

    

 Nothing

157

1.000

 

ref

       

 S-1

30

1.859

0.556

,

6.210

0.314

     

 Capecitabine

125

0.938

0.382

,

2.301

0.888

     

Additional oral steroid days 2 or 3 (vs. Nothing)

312

1.203

0.531

,

2.726

0.658

–

    

NK1RA (vs. Nothing)

312

1.175

0.474

,

2.913

0.728

–

    

Primary organ

312

     

–

    

 colorectal cancer

211

1.000

 

ref

       

 gastric cancer

25

n.c.

         

 lung cancer

23

1.516

0.412

,

5.572

0.531

     

 gynecological cancer

53

0.606

0.173

,

2.131

0.435

     

Hb < 10 mg/dl

312

1.010

0.443

,

2.301

0.981

–

    

Neut < 1500/μl

312

0.528

0.068

,

4.096

0.541

–

    

PLT < 7.5 × 104/μl

312

1.078

0.473

,

2.457

0.858

–

    

CRE ≥1.1 mg/dl

312

6.643

1.848

,

23.881

0.004

12.601

2.437

,

65.157

0.003

AST > 2.5 ULN

312

1.576

0.651

,

3.815

0.313

–

    

ALT > 2.5 ULN

312

1.936

0.767

,

4.890

0.162

–

    

Fever elevation > 38 °C

312

1.696

0.363

,

7.921

0.502

–

    

Constipation

312

1.218

0.506

,

2.933

0.661

–

    

Diarrhea

312

3.241

1.397

,

7.522

0.006

2.594

0.984

,

6.834

0.054

Oral mucositis

312

2.189

0.940

,

5.099

0.069

–

    

Taste alteration

312

1.895

0.833

,

4.314

0.128

–

    

Neuropathy

312

2.916

1.064

,

7.986

0.037

1.088

0.346

,

3.423

0.885

Eruption

312

3.630

1.470

,

8.965

0.005

2.012

0.716

,

5.657

0.185

General fatigue

312

4.085

1.492

,

11.180

0.006

3.728

1.098

,

12.661

0.035

NRS ≥1

312

1.406

0.598

,

3.309

0.435

–

    

PS

312

          

 0

155

1.000

 

ref

  

1.000

 

ref

  

 1

146

3.435

1.215

,

9.708

0.020

2.568

0.820

,

8.043

0.105

 2

11

25.000

5.668

,

110.271

0.000

19.829

3.200

,

122.865

0.001

  1. MEC moderately emetogenic chemotherapy, L-OHP oxaliplatin, CPT-11 irinotecan, CBDCA carboplatin, Hb hemoglobin, Neut neutrophil, PLT platelet, CRE creatine, ULN upper limit of normal, NRS numerical rating scale, PS performance status, OR odds ratio, CI confidence interval